The transaction is sourced from an 8-K filing with the SEC, filed via SEC EDGAR and published on October 6, 2026. The deal's current status is pending regulatory approval.
On the financial advisory side, Perella Weinberg Partners LP and Goldman Sachs & Co. LLC served as financial advisors to Repligen, the acquirer, with no lead designation specified for either firm. Centerview Partners, LLC served as financial advisor to BioLife, the target, also without a specified lead designation.
On the legal side, Goodwin Procter LLP served as legal counsel to Repligen, the acquirer, while K&L Gates LLP served as legal counsel to BioLife, the target.
Beyond the cash and stock consideration mix noted in the deal subtype, no further detail on the specific split between cash and stock components is provided in the facts block.
Several items are not disclosed in the available record. The overall transaction value is not stated in the source document, no lead designation is specified for any of the financial advisors named, the precise cash-versus-stock consideration split is not broken out beyond the general subtype classification, and no expected closing date or further timeline detail beyond the October 2026 filing date and pending-regulatory status is given.